DeVita, Hellman, and Rosenberg's cancer : principles & practice of oncology / / [edited by] Vincent T. DeVita Jr., Theodore S. Lawrence, Steven A. Rosenberg

• Pubblicazione: Philadelphia, : Wolters Kluwer Health/Lippincott Williams & Wilkins, 2015
• Edizione: 10th ed.
• Descrizione fisica: 1 online resource (2280 pages)
• Disciplina: 616.99/4
• Soggetto topico: Cancer; Oncology; Neoplasms
• Altri autori: DeVitaVincent T., Jr., <1935-> LawrenceTheodore S RosenbergSteven A
• Nota di bibliografia: Includes bibliographical references and index.
• Nota di contenuto: Cancer Principles & -- Practice of Oncology -- CONTRIBUTORS -- PREFACE -- Acknowledgments -- CONTENTS -- PART I Principles of Oncology -- 1 Cancer Genome -- introduction -- CANCER GENES AND THEIR MUTATIONS -- IDENTIFICATION OF CANCER GENES -- SOMATIC ALTERATION CLASSES DETECTED BY CANCER GENOME ANALY SIS -- PATHWAY-ORIENTED MODELS OF CANCER GENOME ANALY SIS -- NETWORKS OF CANCER GENOME PROJECTS -- THE GENOMIC LANDSCAPE OF CANCERS -- INTEGRATIVE ANALY SIS OF CANCER GENOMICS -- THE CANCER GENOME AND THE NEW TAXONOMY OF TUMORS -- CANCER GENOMICS AND DRUG RESISTANCE -- PERSPECTIVES OF CANCER GENOME ANALY SIS -- Acknowledgments -- 2 Hallmarks of Cancer: An Organizing Principle for Cancer Medicine -- Introduction -- HALLMARK CAPABILITIES, IN ESSENCE -- TWO UBIQUITOUS CHARACTERISTICS FACILITATE THE ACQUISITION OF HALLMARK CAPABILITIES -- THE CONSTITUENT CELL TYPES OF THE TUMOR MICROENVIRONMENT -- THERAPEUTIC TARGETING OF THE HALLMARKS OF CANCER -- CONCLUSION AND A VISION FOR THE FUTURE -- Acknowledgment -- 3 Molecular Methods in Cancer -- Applications of Molecular Diagnostics in Oncology -- The Clinical Molecular Diagnostics Laboratory: Rules and Regulations -- Specimen Requirements for Molecular Diagnostics -- Molecular Diagnostics Testing Process -- Technologies -- PART II Etiology and Epidemiology of Cancer -- Section 1 Etiology of Cancer -- 4 Tobacco -- introduction -- EPIDEMIOLOGY OF TOBACCO AND CANCER -- CARCINOGENS IN TOBACCO PRODUCTS AND PROCESSES OF CANCER DEVELOPMENT -- 5 Oncogenic Viruses -- PRINCIPLES OF TUMOR VIROLOGY -- PAPILLOMAVIRUSES -- POLYOMAVIRUSES -- EPSTEIN-BARR VIRUS -- KAPOSI's SARCOMA HERPESVIRUS -- ANIMAL AND HUMAN RETRO VIRUSES -- HEPATITIS VIRUSES -- CONCLUSION -- 6 Inflammation -- Introduction -- MOLECULAR BASIS OF INFLAMMATION -- ROLE OF INFLAMMATION IN TRANSFORMATION -- ROLE OF INFLAMMATION IN SURVIVAL. ; ROLE OF INFLAMMATION IN PROLIF ERATION -- ROLE OF INFLAMMATION IN INVASION -- ROLE OF INFLAMMATION IN ANGIOGENESIS -- ROLE OF INFLAMMATION IN META STASIS -- EPIGENETIC CHANGES AND INFLAMMATION -- ROLE OF INFLAMMATION IN CANCER DIAGNOSIS -- INFLAMMATION AND GENOMICS -- INFLAMMATION AND TARGETED THERAPIES -- CONCLUSIONS -- 7 Chemical Factors -- Introduction -- THE NAT URE OF CHEMICAL CARCINOGENS: CHEMISTRY AND META BOLISM -- ANIMAL MODEL SYSTEMS AND CHEMICAL CARCINOGENESIS -- MOLECULAR EPIDEMIOLOGY, CHEMICAL CARCINOGENESIS, AND CANCER RISK IN HUMAN POPULATION S -- ARISTOLO CHIC ACID AND UROT HELIAL CANCERS AS A MODEL FOR IDENTIFYING HUMAN CARCINOGENS -- 8 Physical Factors -- INTRODUCTION -- IONIZING RADIATION -- ULTRAVIOLET LIGHT -- RADIOFREQUENCY AND MICROWAVE RADIATION -- ELECTROMAGNETIC FIELDS -- ASBESTOS -- NANOPARTICLES -- 9 Dietary Factors -- Introduction -- METHODOLOGIC CHALLENGES -- THE ROLE OF INDIVIDUAL FOOD AND NUTRIENTS IN CANCER ETIOLOGY -- OTHER FOODS AND NUTRIENTS -- DIETARY PATTERNS -- DIET DURING THE EARLY PHASES OF LIFE -- DIET AFTER A DIAGNOSIS OF CANCER -- SUMMARY -- LIMITATIONS -- FUTURE DIRECTIONS -- RECOMMENDATIONS -- 10 Obesity and Physical Activity -- INTRODUCTION -- BREAST CANCER -- COLON AND RECTAL CANCER -- ENDOMETRIAL CANCER -- ADENOCARCINOMA OF THE ESOPHAGUS -- KIDNEY/RENAL CELL CANCER -- PANCREATIC CANCER -- GALLBLADDER CANCER -- NON-HODGKIN LYMPHOMA -- PROSTATE CANCER -- LUNG CANCER -- OVARIAN CANCER -- CONCLUSIONS -- Section 2 Epidemiology of Cancer -- 11 Epidemiologic Methods -- Introduction -- ANALYTICAL STUDIES -- INTERPRETATION OF EPIDEMIOLOGIC FINDINGS -- CANCER OUTCOMES RESEARCH -- MOLECULAR EPIDEMIOLOGY -- 12 Trends in United States Cancer Mortality -- INTRODUCTION -- CANCER SURVEILLANCE SYSTEMS -- MAKING SENSE OF CANCER TRENDS -- TRENDS IN CANCER RISK FACTORS AND SCREENING -- CANCER INCIDENCE AND MORTALITY. ; PREDICTING FUTURE CANCER TRENDS -- PART III Cancer Therapeutics -- 13 Essentials of Radiation Therapy -- INTRODUCTION -- BIOLOGIC ASPECTS OF RADIATION ONCOLOGY -- FACTORS THAT AFFECT RADIATION RESPONSE -- DRUGS THAT AFFECT RADIATION SENSITIVITY -- RADIATION PHYSICS -- TREATMENT PLANNING -- OTHER TREATMENT MODALITIES -- CLINICAL APPLICATIONS OF RADIATION THERAPY -- TREATMENT INTENT -- FRACTIONATION -- ADVERSE EFFECTS -- PRINCIPLES OF COMBINING ANTICANCER AGENTS WITH RADIATION THERAPY -- 14 Cancer Immunotherapy -- Introduction -- HUMAN TUMOR ANTIGENS -- HUMAN CANCER IMMUNOTHERAPIES -- 15 Pharmacokinetics and Pharmacodynamics of Anticancer Drugs -- INTRODUCTION -- PHARMACOKINETIC CONCEPTS -- PHARMACODYNAMIC CONCEPTS -- VARIABILITY IN PHARMACOKINETICS/ PHARMACODYNAMICS -- DOSE-ADAPTATION USING PHARMACOKINETIC/PHARMACODYNAMIC PRINCIPLES -- 16 Pharmacogenomics -- Introduction -- PHARMACOGENOMICS OF TUMOR RESPONSE -- PHARMACOGENOMICS OF CHEMOTHERAPY DRUG TOXICITY -- CONCLUSIONS AND FUTURE DIRECTIONS -- 17 Alkylating Agents -- PERSPECTIVES -- CHEMISTRY -- CLASSIFICATION -- CLINICAL PHARMACOKINETICS/ PHARMACODYNAMICS -- THERAPEUTIC USES -- TOXICITIES -- COMPLICATIONS WITH HIGH-DOSE ALKYLATING AGENT THERAPY -- ALKYLATING AGENT-STEROID CONJUGATES -- DRUG RESISTANCE AND MODULATION -- RECENT DEVELOPMENTS -- 18 Platinum Analogs -- Introduction -- HISTORY -- PLATINUM CHEMISTRY -- PLATINUM COMPLEXES AFTER CISPLATIN -- MECHANISM OF ACTION -- CELLULAR RESPONSES TO PLATINUM-INDUCED DNA DAMAGE -- IS DNA THE ONLY TARGET? -- MECHANISMS OF RESISTANCE -- CLINICAL PHARMACO LOGY -- FORMULATION AND ADMINISTRATION -- TOXICITY -- 19 Antimetabolites -- ANTIFOLATES -- 5-FLUOROPYRIMIDINES -- CAPECITABINE -- CYTARABINE -- GEMCITABINE -- 6-THIOPURINES -- FLUDARABINE -- CLADRIBINE -- CLOFARABINE -- 20 Topoisomerase Interactive Agents. ; CLASSIFICATION, BIOCHEMICAL, AND BIOLOGIC FUNCTIONS OF TOPOISOMERASES -- TOPOISOMERASE INHIBITORS AS INTERFACIAL POISONS -- Topoisomerase I Inhibitors : Camptothecins and Beyond -- TOPOISOMERASE II INHIBITORS: INTERCALATORS AND NONINTERCALATORS -- THERAPY-RELATED SECONDARY ACUTE LEUKEMIA -- FUTURE DIRECTIONS -- 21 Agents -- MICROTUBULES -- TAXANES -- VINCA ALKALOIDS -- MICROTUBULE ANTAGONISTS -- MITOTIC MOTOR PROTEIN INHIBITORS -- MECHANISMS OF RESISTANCE TO MICROTUBULE INHIBITORS -- 22 Kinase Inhibitors as Anticancer Drugs -- INTRODUCTION -- EARLY SUCCESSES: TAR GETING CANCERS WITH WELL-KNOWN KINASE MUTATI ONS (BCR-ABL, KIT, HER2) -- DIRECTLY TARGETING THE PI3K PATH WAY -- COMBINATIONS OF KINASE INHIBITORS TO INDUCT RESPONSE AND PREVENT RESISTANCE -- SPECULATI ONS ON THE FUTURE ROLE OF KINASE INHIBITORS IN CANCER MEDICINE -- 23 Histone Deacetylase Inhibitors and Demethylating Agents -- INTRODUCTION -- EPIGENETIC ABNORMALITIES AND GENE EXPRESSION CHANGES IN CANCER -- HISTONE DEACETYLASE INHIBITORS -- EPIGENETIC THERAPY FOR HEMATOLOGIC MALIGNANCIES -- NEW APROACHES TO EPIGENETIC THERAPY -- 24 Proteasome Inhibitors -- BIOCHEMISTRY OF THE UBIQUITIN-PROTEASOME PATHWAY -- PROTEASOME INHIBITORS -- PROTEASOME INHIBITORS IN CANCER -- 25 Poly (ADP-ribose) Polymerase Inhibitors -- INTRODUCTION -- CELLULAR DNA REPAIR PATHWAYS -- THE DEVELOPMENT OF PARP INHIBITORS -- BRCA1 AND BRCA2 MUTATIONS AND DNA REPAIR -- PARP -1 INHIBITION AS A SYNTHETIC LETHAL THERAPEUTIC STRATE GY FOR THE TREAT MENT OF BRCA -DEFICIENT CANCERS -- INITIAL CLINICAL RESULTS TESTING SYNTHETIC LETHALITY OF PARP INHIBITORS AND BRCA MUTATION -- THE USE OF PARP INHIBITORS IN SPORADIC CANCERS -- MECHANISMS OF RESISTANCE TO PARP INHIBITORS -- PROSPECTS -- 26 Miscellaneous Chemotherapeutic Agents -- HOMOHARRINGTONINE AND OMACETAXINE -- L-ASPARAGINASE -- BLEOMYCIN -- PROCARBAZINE. ; SIROLIMUS AND TEMSIROLIMUS -- VISMODEGIB -- ADO-TRASTUZUMAB EMTANSINE -- SIROLIMUS AND TEMSIROLIMUS -- EVEROLIMUS -- THALIDOMIDE, LENALIDOMIDE, AND POMALIDOMIDE -- 27 Hormonal Agents -- Introduction -- SELECTIVE ESTROGEN RECEPTOR MODULATORS -- AROMATASE INHIBITORS -- GONADOTROPIN-RELEASING HORMONE ANALOGS -- GONADOTROPIN-RELEASING HORMONE ANTAGONISTS -- ANTIANDROGENS -- NOVEL ANTIANDROGENS -- OTHER SEX STEROID THERAPIES -- OTHER HORMONAL THERAPIES -- 28 Antiangiogenesis Agents -- INTRODUCTION -- UNDERSTANDING THE ANGIOGENIC PROCESS -- DRUG DEVELOPMENT OF ANGIOGENESIS INHIBITORS -- CLINICAL UTILITY OF APPROVED ANTIANGIOGENIC AGENTS IN CANCER THERAPY -- COMBINATION THERAPIES -- BIOMARKERS OF ANTIANGIOGENIC THERAPY -- RESISTANCE TO ANTIANGIOGENIC THERAPY -- 29 Monoclonal Antibodies -- INTRODUCTION -- IMMUNOGLOBULIN STRUCTURE -- MODIFIED ANTIBODY-BASED MOLECULES -- FACTORS REGULATING ANTIBODY-BASED TUMOR TARGETING -- UNCONJUGATED ANTIBODIES -- ALTERING SIGNAL TRANSDUCTION -- IMMUNOCONJUGATES -- ANTIBODIES APPROVED FOR USE IN SOLID TUMORS -- ANTIBODIES USED IN HEMATOLOGIC MALIGNANCIES -- CONCLUSION -- 30 Assessment of Clinical Response -- INTRODUCTION -- ASSESSING RESPONSE -- ALTERNATE RESPONSE CRITERIA -- DETERMINING OUTCOME -- PART IV Cancer Prevention and Screening -- 31 Tobacco Use and the Cancer Patient -- Introduction -- NEUROBIOLOGY OF TOBACCO DEPENDENCE -- TOBACCO USE PREVALENCE AND THE EVOLUTION OF TOBACCO PRODUCTS -- TOBACCO USE BY THE CANCER PATIENT -- THE CLINICAL EFFECTS OF SMOKING ON THE CANCER PATIENT -- ADDRESSING TOBACCO USE BY THE CANCER PATIENT -- FUTURE CONSIDERATIONS -- 32 Role of Surgery in Cancer Prevention -- INTRODUCTION -- PATIENTS AT HIGH RISK FOR BREAST CANCER -- HEREDITARY DIFFUSE GASTRIC CANCER -- SURGICAL PROPHYLAXIS OF HEREDITARY OVARIAN AND ENDOMETRIAL CANCER -- HEREDITAR Y ENDOMETRIAL CANCER (LYNCH SYNDRO ME). ; GYNECOLOGIC CANCER RISK IN VERY RARE HEREDITARY CANCER SYNDRO MES.
• Sommario/riassunto: "Cancer: Principles and Practice of Oncology presents the practicing oncologist with the practical as well as cutting-edge information needed to ensure the best possible care for each individual patient. To ensure a balanced multidisciplinary approach, a surgeon, a medical oncologist, and a radiation oncologist author each of the major treatment chapters. Each of the major treatment sections is preceded by an updated, brief chapter describing the molecular biology of that cancer and the prospects this new information holds for the improved management of cancer patients"--
• Altri titoli varianti: Cancer : principles & practice of oncology
• Titolo autorizzato: DeVita, Hellman, and Rosenberg's cancer
• ISBN: 1-4698-9455-6; 1-4963-2467-6
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910807121703321
• Lo trovi qui: Univ. Federico II